Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $15.00.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, February 5th. JPMorgan Chase & Co. reissued a “sell” rating on shares of Jounce Therapeutics in a report on Thursday, March 7th.
JNCE stock traded down $0.04 during mid-day trading on Monday, hitting $4.45. The stock had a trading volume of 96,700 shares, compared to its average volume of 203,984. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.24 and a quick ratio of 2.24. Jounce Therapeutics has a 1-year low of $2.66 and a 1-year high of $9.20. The firm has a market cap of $146.73 million, a P/E ratio of -5.30 and a beta of 3.57.
Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Jounce Therapeutics had a negative return on equity of 26.05% and a negative net margin of 41.13%. The firm had revenue of $10.98 million during the quarter, compared to analyst estimates of $14.75 million. As a group, research analysts expect that Jounce Therapeutics will post -1.2 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Man Group plc acquired a new position in shares of Jounce Therapeutics during the 1st quarter valued at about $121,000. Oxford Asset Management LLP increased its holdings in shares of Jounce Therapeutics by 207.3% during the 1st quarter. Oxford Asset Management LLP now owns 129,789 shares of the company’s stock valued at $805,000 after acquiring an additional 87,558 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Jounce Therapeutics by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 94,743 shares of the company’s stock valued at $588,000 after buying an additional 10,325 shares during the last quarter. AQR Capital Management LLC grew its holdings in Jounce Therapeutics by 194.6% in the 1st quarter. AQR Capital Management LLC now owns 387,175 shares of the company’s stock valued at $2,400,000 after buying an additional 255,732 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Jounce Therapeutics in the 1st quarter valued at approximately $96,000. 73.29% of the stock is currently owned by institutional investors and hedge funds.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Read More: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.